Trials / Conditions / Stage IIIA Fallopian Tube Cancer AJCC v7

Stage IIIA Fallopian Tube Cancer AJCC v7

18 registered clinical trials studyying Stage IIIA Fallopian Tube Cancer AJCC v7.

Status	Trial	Sponsor	Phase
Completed	Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, NCT02713386	NRG Oncology	Phase 1 / Phase 2
Withdrawn	Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With NCT03902379	Rutgers, The State University of New Jersey	N/A
Active Not Recruiting	Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontl NCT02726997	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, NCT02520154	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary P NCT02659241	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tu NCT02316834	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopia NCT02042430	National Cancer Institute (NCI)	EARLY_Phase 1
Active Not Recruiting	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid T NCT02142803	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopi NCT01970722	City of Hope Medical Center	Phase 1
Unknown	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previo NCT00719303	Gynecologic Oncology Group	Phase 3
Completed	Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian NCT01504126	M.D. Anderson Cancer Center	EARLY_Phase 1
Unknown	Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovar NCT01366183	Gynecologic Oncology Group	—
Unknown	Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, NCT01372787	Gynecologic Oncology Group	—
Active Not Recruiting	Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy i NCT01081262	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage NCT01167712	National Cancer Institute (NCI)	Phase 3
Completed	Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovar NCT00989651	National Cancer Institute (NCI)	Phase 1
Unknown	Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Ut NCT00954174	GOG Foundation	Phase 3
Unknown	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian E NCT00108745	GOG Foundation	Phase 3